What`s New for 2022?

» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year

Global Renal Denervation Technologies Market to Reach $745.7 Million by 2026

Renal denervation refers to a catheter-based interventional therapy wherein a catheter is placed into a patient`s renal artery to make way for the delivery of radiofrequency energy in order to ablate the nerves in the vessel wall of the renal arteries that regulate vasoconstriction. Such a position leaves the vessel to continuously remain in the widest open position to enable higher flow of blood to the kidneys, allowing more blood to be filtered and excess water to be removed helping lower hypertension. The demand for renal denervation systems is growing steadily led by increase in prevalence of hypertension, growing base of geriatric population, longer lasting effect of the renal denervation procedure and its minimal complications and faster recovery time. Additional factors favoring growth include improving healthcare infrastructure in emerging economies, affordability of the procedure, and technological innovations focused on the development of such alternative technologies as micro-infusion-based renal denervation systems. The demand of these systems is expected to grow as more clinical trials are conducted to establish efficacy and cost-effectiveness of renal denervation procedure as against traditional surgeries.

Amid the COVID-19 crisis, the global market for Renal Denervation Technologies estimated at US$183.8 Million in the year 2022, is projected to reach a revised size of US$745.7 Million by 2026, growing at a CAGR of 37.3% over the analysis period. Radiofrequency Based, one of the segments analyzed in the report, is projected to grow at a 36.8% CAGR to reach US$729.9 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Ultrasound Based segment is readjusted to a revised 39.2% CAGR for the next 7-year period. This segment currently accounts for a 22.4% share of the global Renal Denervation Technologies market. Radiofrequency, owing to efficiency, safety and minimal time taken, is the most commonly used renal denervation technology with a dominating market share. Key factor favoring increase in demand for ultrasound-based renal denervation is its ability to overcome the shortcomings of radiofrequency-based renal denervation. The ultrasound-based technology uses high-frequency sound waves to ablates the nerves without establishing any contact with the tissues resulting in minimal injury to the renal arteries.

The U.S. Market is Estimated at $47 Million in 2022, While China is Forecast to Reach $49.5 Million by 2026

The Renal Denervation Technologies market in the U.S. is estimated at US$47 Million in the year 2022. The country currently accounts for a 25.46% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$49.5 Million in the year 2026 trailing a CAGR of 50.6% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 30.9% and 35.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 35.6% CAGR while Rest of European market (as defined in the study) will reach US$71.9 Million by the end of the analysis period. Europe dominates market share, driven by increasing number of drug-resistant hypertension cases, greater research and development initiatives for developing efficient devices, and approval of advanced renal denervation devices. Another key market, growth in the US is expected to be driven by escalating uncontrolled hypertension cases and increasing petitions for product authorizations.

Micro-Infusion Based Segment to Reach $38.1 Million by 2026

Micro-infusion based renal denervation focuses on delivering agents at a specific site to denervate the renal artery in order to reduce the blood pressure of the patient. As the approach involves direct and non-systemic injection of therapeutic agents, the method tends to be safe and more effective. In the global Micro-Infusion Based segment, USA, Canada, Japan, China and Europe will drive the 33.5% CAGR estimated for this segment. These regional markets accounted for a combined market size of US$5.8 Million. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.5 Million by the year 2026.